Published • loading... • Updated
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
Curis will also discuss emavusertib development, including substantially complete AML studies and ongoing lymphoma and CLL combination trials.
- On Tuesday, May 12, 2026, Curis, Inc. will report its first quarter 2026 financial and operating results at 4:00 p.m. ET, with the LEXINGTON, Mass. company hosting the announcement.
- Through a 2015 collaboration with Aurigene Discovery Technologies Limited, Curis maintains an exclusive license to Emavusertib, an IRAK4 and FLT3 inhibitor serving as the Company's primary development focus.
- Clinical evaluations include the TakeAim Lymphoma Phase 1/2 study and the TakeAim CLL Phase 2 study , which test the drug in combination therapies.
- The United States Food and Drug Administration granted Orphan Drug Designation for PCNSL, AML, and MDS treatment, while the European Commission provided this designation specifically for PCNSL.
- Management will host a conference call and simultaneous webcast at 4:30 p.m. ET on the same day, with live audio access available from the investor section of the Curis website.
Insights by Ground AI
18 Articles
18 Articles
The Berkshire Eagle+17 Reposted by 17 other sources
Curis to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on May 12, 2026
LEXINGTON, Mass., May 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its first quarter…
Coverage Details
Total News Sources18
Leaning Left2Leaning Right4Center7Last UpdatedBias Distribution54% Center
Bias Distribution
- 54% of the sources are Center
54% Center
15%
C 54%
R 31%
Factuality
To view factuality data please Upgrade to Premium
